000			03196nam a22003737a 4500
008			240723s20242024 xxu||||| |||| 00| 0 eng d
022			_a2520-8934
024			_a10.1186/s42155-024-00438-6 [pii]
024			_aPMC10957860 [pmc]
040			_aOvid MEDLINE(R)
099			_a38514484
245			_aIliocaval and iliofemoral venous stenting for obstruction secondary to tumor compression.
251			_aCVIR Endovascular. 7(1):33, 2024 Mar 22.
252			_aCVIR Endovasc. 7(1):33, 2024 Mar 22.
253			_aCVIR endovascular
260			_c2024
260			_p2024 Mar 22
260			_fFY2024
265			_sepublish
265			_tPubMed-not-MEDLINE
520			_aBACKGROUND: Cancer patients with pelviabdominal masses can suffer from lower extremity symptoms due to venous compression. The effectiveness of venous stenting has been established in extrinsic venous compression in benign conditions like May-Thurner syndrome. In this retrospective study we evaluate the efficacy and safety of caval, iliocaval and iliofemoral venous stenting for cases of extrinsic venous compression caused by malignant masses in cancer patients.
520			_aCONCLUSION: Venous stenting is a safe procedure and should be considered as part of the palliative care for patients with debilitating lower extremity symptoms related to iliocaval and iliofemoral venous compression. Copyright © 2024. The Author(s).
520			_aMETHODS: IRB-approved retrospective review of patients who underwent iliofemoral venography with venoplasty and stenting between January 2018 and February 2022 was performed. Patients with extrinsic venous compression caused by malignant masses were included. Data on patient demographics, pre-procedure symptoms, procedural technique, stent characteristics, outcomes and follow-up were collected. Descriptive statistics were used to assess technical success, clinical success, primary stent patency and adverse events of the procedure.
520			_aRESULTS: Thirty-seven patients (19 males, 18 females) who underwent 45 procedures were included. Deep venous thrombosis (DVT) was present in 21 (57%) patients. Twenty-nine patients (78%, 95% CI 62-90%) reported clinical improvement of the presenting symptoms. The median overall survival after the procedure was 4.7 months (95% CI 3.58-5.99). Eight (22%) patients were alive at last follow up with median follow up of 10.33 months (Range 2-25 months). Twenty-six patients had patent stents on their last follow up imaging (70%, 95% CI 61%-91%). Two patients had a small access site hematoma which resolved spontaneously. Two patients developed moderate, and 1 patient developed severe adverse events related to post procedure therapeutic anticoagulation.
546			_aEnglish
650			_zAutomated
651			_aMedStar Washington Hospital Center
656			_aRadiology
657			_aJournal Article
700			_aAly, Ahmed K _bMWHC
790			_aAly AK, Moussa AM, Chevallier O, Kishore S, Petre E, Friedman A, Bryce Y, Gonzalez A, Camacho J, Santos E, Ridouani F
856			_uhttps://dx.doi.org/10.1186/s42155-024-00438-6 _zhttps://dx.doi.org/10.1186/s42155-024-00438-6
942			_cART _dArticle
999			_c14257 _d14257